NCT01655381View on ClinicalTrials.gov

A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Tocilizumab

Tocilizumab 8 mg/kg administered intravenously.

Trial Locations (6)

31059

Toulouse

34295

Montpellier

45032

Orléans

46005

Cahors

68070

Mulhouse

75651

Paris

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01655381 - A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter